Research programme: cancer therapeutics - Evotec
Latest Information Update: 28 Feb 2024
Price :
$50 *
At a glance
- Originator Evotec SE
- Developer Evotec SE; Indivumed
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer; Non-small cell lung cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in Non-small-cell-lung-cancer in Germany
- 28 May 2023 No recent reports of development identified for research development in Colorectal-cancer in Germany
- 23 Jan 2020 Evotech and Indivumed agree to co-develop cancer therapeutics in Germany for Non-small cell lung cancer